| First Author | Jawień J | Year | 2007 |
| Journal | J Physiol Pharmacol | Volume | 58 |
| Issue | 3 | Pages | 583-8 |
| PubMed ID | 17928652 | Mgi Jnum | J:130080 |
| Mgi Id | MGI:3770717 | Citation | Jawien J, et al. (2007) BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 58(3):583-8 |
| abstractText | Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by 'en face' method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and 'cross-section' method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice. |
